Literature DB >> 1717550

Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy.

C C Whitacre1, I E Gienapp, C G Orosz, D M Bitar.   

Abstract

We have recently reported that experimental autoimmune encephalomyelitis (EAE) can be suppressed by the oral administration of myelin basic protein (MBP). The oral introduction of 20 mg MBP together with a trypsin inhibitor results in inhibition of EAE clinical signs, decreased CNS histopathologic changes and dramatically reduced MBP-specific proliferative responses in fed and challenged Lewis rats. In the present study, we have investigated the mechanism underlying MBP-induced oral tolerance in EAE. Neither lymphoid cells (lymph node cells, spleen cells, Peyer's patch lymphocytes, thymocytes) nor humoral elements derived from tolerant donors were capable of transferring the tolerance to naive recipients. Moreover, lymphoid cells obtained from orally tolerant donors exhibited a marked decrease in their capacity to transfer EAE to naive recipient rats, even after in vitro activation with MBP or Con A. We observed that EAE could be readily transferred into orally tolerant rats using MBP-specific encephalitogenic T cell lines. In vitro cell mixing studies showed that the proliferation of lymphocytes from MBP-sensitized donors was not inhibited by the addition of lymphoid cells from tolerant donors, arguing against the role of a suppressor cell. Investigation of MBP-stimulated lymphokine production showed that both IL-2 and IFN-gamma levels were substantially decreased in spleen and lymph node cell cultures from MBP-fed rats compared to vehicle-fed control animals. Furthermore, limiting dilution analyses revealed that MBP-fed rats exhibited a profound decrease in MBP-reactive, IL-2-secreting lymphocytes relative to control animals. Thus, because lymphocytes from MBP-fed rats neither proliferate nor secrete IL-2 or IFN-gamma in response to MBP and we can find no compelling evidence for the role of suppressor cells, we propose that the oral administration of MBP results in a state of clonal anergy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717550

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes.

Authors:  B S Lundin; M R Karlsson; L A Svensson; L A Hanson; U I Dahlgren; E Telemo
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  Oral tolerance, an active immunologic process mediated by multiple mechanisms.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

5.  Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance.

Authors:  K S Barone; B Herms; L Karlosky; S Murray; J Qualls
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

6.  Multiple fragments of human TG are capable of inducing oral tolerance to whole human TG.

Authors:  C A Gardine; F Gentile; C Pellegrini; F Giallauria; G Torelli; T Kouki; L DeGroot
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

7.  An investigation of the ability of orally primed and tolerised T cells to help B cells upon mucosal challenge.

Authors:  Natalie Kobets; Kim Kennedy; Deborah O'Donnell; Paul Garside
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

8.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

9.  Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.

Authors:  T Bárdos; M Czipri; C Vermes; J Zhang; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

10.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.